title: Capecitabine plus oxaliplatin (xelox) in the treatment of chemotherapy-naive patients with metastatic colorectal cancer.
abstract: BACKGROUND
  Capecitabine and oxaliplatin are both synergistically active against metastatic colorectal cancer (MCRC). We evaluated our experience at two centers with capecitabine and oxaliplatin combination (XELOX) in previously untreated patients with MCRC.
  
  
  METHODS
  We reviewed medical records of 85 previously untreated patients with MCRC who received first-line XELOX regimen. Oxaliplatin was given at a dose of 130 mg/m2 on day 1 in combination with capecitabine 1500 mg/m2/day on days 1-14 every 3 weeks.
  
  
  RESULTS
  Seventy-six of 85 patients were evaluated for response and toxicity. Patients with a follow up of less than 6 months were excluded from the study. Objective response rate was 46% including 8 complete responses (10.5%) and 27 partial responses (35.5%). Additionally, 20 patients (26.3%) had disease stabilization at least 3 months after the treatment. The patients were followed for a median 12.5 months (range 2-32). Median time to disease progression (TTP) was 11 months (range 2-27 months). Median overall survival (OS) time has not yet been reached. One-year survival rate was 66%. Toxicity was modest with infrequent grade 3-4 adverse effects.
  
  
  CONCLUSIONS
  XELOX is an active regimen against MCRC in the first-line setting with favorable toxicity profile. Our results appear to be comparable, if not superior, to the results of other reports of first-line XELOX therapy in respect to objective response rates, survival data, and safety profile. Convenience with oral administration of every 3-week schedule makes XELOX regimen a compelling therapeutic option in the treatment of first-line MCRC.
authors.affiliation: Department of Medical Oncology, Gazi University Medical School, Besevler, Ankara, Turkey.
authors.forename: Emel
authors.initials: E
authors.lastname: Yaman
authors.forename: Aytug
authors.initials: A
authors.lastname: Uner
authors.forename: Ozlem
authors.initials: O
authors.lastname: Er
authors.forename: Ugur
authors.initials: U
authors.lastname: Coskun
authors.forename: Suleyman
authors.initials: S
authors.lastname: Buyukberber
authors.forename: Mustafa
authors.initials: M
authors.lastname: Dikilitas
authors.forename: Mevlude
authors.initials: M
authors.lastname: Polat
authors.forename: Deniz
authors.initials: D
authors.lastname: Yamac
authors.forename: Ali Osman
authors.initials: AO
authors.lastname: Kaya
authors.forename: Ramazan
authors.initials: R
authors.lastname: Yildiz
authors.forename: Banu
authors.initials: B
authors.lastname: Ozturk
authors.forename: Mustafa
authors.initials: M
authors.lastname: Benekli
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols; D000069287:Capecitabine; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018572:Disease-Free Survival; D004338:Drug Combinations; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000627:therapeutic use*; D010071:Oxaloacetates; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D004338:Drug Combinations; D009944:Organoplatinum Compounds; D010071:Oxaloacetates; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil